127 related articles for article (PubMed ID: 11261540)
1. Mifepristone: less obvious adverse effects.
Rudd G
Ann Pharmacother; 2001 Mar; 35(3):381-2. PubMed ID: 11261540
[No Abstract] [Full Text] [Related]
2. Mifepristone--a boom or a bust?
Willke JC
Ann Pharmacother; 2001 Mar; 35(3):376-80. PubMed ID: 11261539
[No Abstract] [Full Text] [Related]
3. Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.
Cleland K; Smith N
Contraception; 2015 Sep; 92(3):179-81. PubMed ID: 26093188
[No Abstract] [Full Text] [Related]
4. Abortifacient drug approved for restricted, physician-only distribution.
Miller JL
Am J Health Syst Pharm; 2000 Nov; 57(21):1940. PubMed ID: 11094643
[No Abstract] [Full Text] [Related]
5. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
Hausknecht RU
Ann Pharmacother; 2006 Apr; 40(4):785-6; author reply 786. PubMed ID: 16569806
[No Abstract] [Full Text] [Related]
6. Fatal infections associated with mifepristone-induced abortion.
Greene MF
N Engl J Med; 2005 Dec; 353(22):2317-8. PubMed ID: 16319378
[No Abstract] [Full Text] [Related]
7. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
Shannon CS
Ann Pharmacother; 2006 Jun; 40(6):1215-6; author reply 1216-7. PubMed ID: 16735658
[No Abstract] [Full Text] [Related]
8. Rupture in an unscarred uterus during second trimester pregnancy termination with mifepristone and misoprostol.
Bagga R; Chaudhary N; Kalra J
Int J Gynaecol Obstet; 2004 Oct; 87(1):42-3. PubMed ID: 15464778
[No Abstract] [Full Text] [Related]
9. Abortion pill gets FDA approval.
SoRelle R
Circulation; 2000 Oct; 102(15):E9030-1. PubMed ID: 11183868
[No Abstract] [Full Text] [Related]
10. New warning for mifepristone and misoprostol.
Lancet; 2005 Jul 30-Aug 5; 366(9483):344. PubMed ID: 16075477
[No Abstract] [Full Text] [Related]
11. Thrombotic thrombocytopenic purpura secondary to mifepristone in a patient of medical termination in early pregnancy.
Chung LW; Yeh SP; Hsieh CY; Chiu CF
Ann Hematol; 2007 May; 86(5):385-6. PubMed ID: 17180387
[No Abstract] [Full Text] [Related]
12. Atypical presentation of serious pelvic inflammatory disease following mifepristone-induced medical abortion.
Sparrow M; Shand C; Macdonald J
Contraception; 2006 Oct; 74(4):352-3; author reply 353-4. PubMed ID: 16982242
[No Abstract] [Full Text] [Related]
13. Mifepristone for termination of early pregnancy.
FDA Consum; 2000; 34(6):7. PubMed ID: 11192820
[No Abstract] [Full Text] [Related]
14. Mifepristone for medical abortion. Exploring a new option for nurse practitioners.
Taylor D; Hwang AC
AWHONN Lifelines; 2003 Dec-2004 Jan; 7(6):524-9. PubMed ID: 14753095
[No Abstract] [Full Text] [Related]
15. Risks of mifepristone abortion in context.
Grimes DA
Contraception; 2006 Aug; 74(2):174-5 author reply175-6. PubMed ID: 16860058
[No Abstract] [Full Text] [Related]
16. Risks of mifepristone abortion in context.
Crockett SA
Contraception; 2006 Aug; 74(2):174; author reply 175-6. PubMed ID: 16860057
[No Abstract] [Full Text] [Related]
17. Use of mifepristone for medical abortion in Australia, 2006-2009.
de Costa CM
Med J Aust; 2011 Feb; 194(4):206-7. PubMed ID: 21401466
[No Abstract] [Full Text] [Related]
18. Mortality associated with mifepristone-misoprostol medical abortion.
Creinin M; Blumenthal P; Shulman L
MedGenMed; 2006 Apr; 8(2):26. PubMed ID: 16926765
[No Abstract] [Full Text] [Related]
19. The long, winding road of RU-486.
Check E
Newsweek; 2000 Oct; 136(14):50. PubMed ID: 11183341
[No Abstract] [Full Text] [Related]
20. Public health advisory for mifepristone.
FDA Consum; 2005; 39(5):4-5. PubMed ID: 16421985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
